Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Efficacy and safety of direct antiviral agents in a cohort of cirrhotic HCV/HIV-coinfected patients.

The Journal of antimicrobial chemotherapy - 1 Oct 2017

Navarro Jordi, Laguno Montserrat, Vilchez Helem Haydee, Guardiola Jose M, Carrion Jose A, Force Luis, Cairó Mireia, Cifuentes Carmen, Vilaró Josep, Cucurull Josep, Marco Andrés, Roget Mercè, Erice Eva, Crespo Manuel

Abstract excerpt

Background: New direct-acting antiviral agents (DAAs) have shown great efficacy and tolerability in clinical trials and real-life cohorts. However, data are scarce regarding efficacy and safety in cirrhotic HCV/HIV-coinfected patients. Methods: A multicentre prospective analysis was performed in 13 Spanish hospitals, including all cirrhotic HCV/HIV-coinfected patients starting DAA combinations from January to...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Benzimidazoles
Share to Coinfection

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Fluorenes

Share to Simeprevir

Share to Sofosbuvir

Share to Sustained Virologic Response

Share to Uridine Monophosphate

Source

Identifiers

PMID: 29091196
DOI: 10.1093/jac/dkx223

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Efficacy and safety of direct antiviral agents in a cohort of cirrhotic HCV/HIV-coinfected patients.PMID 29091196Read ↗

HCV mono-infected and HIV/HCV co-infected individuals treated with direct-acting antivirals: to what extent do they differ?Semantic proximity Read ↗

Treatment of genotype 1 HCV infection in the HIV coinfected patient in 2014.Semantic proximity Read ↗

Daclatasvir plus sofosbuvir, with or without ribavirin, in real-world patients with HIV-HCV coinfection and advanced liver disease.Semantic proximity Read ↗

Advances in the treatment of HIV/HCV coinfection in adults.Semantic proximity Read ↗

Treatment of hepatitis C in patients with cirrhosis: remaining challenges for direct-acting antiviral therapy.Semantic proximity Read ↗

Real-Life Experience of Hepatitis C Treatment with Direct-Acting Antivirals in Genotypes 2 and 3.Semantic proximity Read ↗

Changes in characteristics of patients with hepatitis C virus-related cirrhosis from the beginning of the interferon-free era.Semantic proximity Read ↗

Antiviral Therapy in Patients with Hepatitis C Virus-Induced Cirrhosis.Semantic proximity Read ↗

Real life efficacy and safety of direct-acting antiviral therapy for treatment of patients infected with hepatitis C virus genotypes 1, 2 and 3 in northwest China.Semantic proximity Read ↗

Are There Still Difficult-to-Treat Patients with Chronic Hepatitis C in the Era of Direct-Acting Antivirals?Semantic proximity Read ↗

Use of Daclatasvir in HCV/HIV-Coinfected Patients in a Real-Life Setting.Semantic proximity Read ↗

The hepatitis C revolution part 1: antiviral treatment options.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.